Empagliflozin reduces brain pathology in Alzheimer's disease and type 2 diabetes
Carmen Hierro-Bujalance1
Monica Garcia-Alloza2
1.Division of Physiology,School of Medicine,Universidad de Cadiz,Cadiz,Spain;Instituto de Investigacion e Innovacion en Ciencias Biomedicas de la Provincia de Cadiz (INIBICA),Cadiz,Spain (Hierro-Bujalance C,Garcia-Alloza M)Salus Infirmorum-Universidad de Cadiz,adiz,Spain2.Division of Physiology,School of Medicine,Universidad de Cadiz,Cadiz,Spain
摘要：Alzheimer's disease(AD)and type 2 diabetes(T2D):More than 55 million people suffer from dementia,and it is expected that over 150 million people will suffer from this disease by 2050.AD is the most common type of dementia and while aging remains the main risk factor to suffer it,previous studies have also shown that metabolic disorders,and T2D specifically,are also major contributors(Wang et al.,2012).The prevalence of diabetes has reached 537 million people worldwide and these figures are expected to keep rising(Ahmad et al.,2022).All things considered,both diseases are a great challenge for health professionals as well as a major social problem.
机标关键词：empagliflozinalzheimerbraindiabetesdiseasepathologyreducestype
论文发表日期：2024-06-28
在线出版日期：2025-08-15（本平台首次上网日期，不代表文献的发表时间）
页数：2( 1189-1190 )